344 Results (Page 2 of 14)
Malaysia Markets Research Reports
Malaysia Electronic Health Records Market Analysis
Malaysia's Electronic Health Records (EHR) market size was valued at $xx Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of xx% from 2022 to 2030 and will reach $XX Bn in 2030. The market is segmented by product, application, and end user. The Malaysia EHR market will grow due to government initiatives to promote the adoption of EHRs. The key market players are Epic Systems Allscripts, McKesson, and others.
Malaysia Chronic Pain Therapeutics Market Analysis
The Malaysia Chronic Pain Therapeutics Market is anticipated to experience a growth from $119 Mn in 2022 to $192 Mn by 2030, with a CAGR of 6.1% during the forecast period of 2022-2030. Malaysia is witnessing market growth due to factors such as the growing awareness of chronic pain, supported by governmental initiatives aimed at improving access to treatment and the escalating burden of chronic pain. The Malaysia Chronic Pain Therapeutics Market encompasses various players across different segments, including Pfizer, AstraZeneca, Sanofi, Merck, Roche, AbbVie, Novartis, Duopharma, Pharmaniaga, Healthex, etc., among various others.
Malaysia Artificial Intelligence (AI) in Healthcare Market Analysis
The Malaysia Artificial Intelligence (AI) In Healthcare Market is projected to grow from $0.01 Bn in 2022 to $0.22 Bn by 2030, registering a CAGR of 45.42% during the forecast period of 2022 - 2030. The market will be driven by the collaborative efforts from the government & private sectors and the introduction of structured regulations & guidelines for the use of AI in healthcare. The market is segmented by healthcare components & by healthcare applications. Some of the major players include Microsoft Healthcare, Naluri & Nova MSC Bhd.
Malaysia Biomaterials in Healthcare Market Analysis
Malaysia Biomaterials in Healthcare Market is expected to witness growth from $251 Mn in 2022 to $687 Mn in 2030 with a CAGR of 13.40% for the forecasted year 2022-30. Malaysia is seeing an increase in demand for cosmetic and plastic surgery due to growing disposable incomes and the availability of reasonably priced, high-quality healthcare services. Because biomaterials are frequently used in these procedures, manufacturers have chances to supply the market. The market is segmented by type and by application. Some key players in this market include Bioalpha Holdings Berhad, Biocon Sdn Bhd, Hovid Berhad, BASF SE, Johnson and Johnson, Medtronic and Evonik Industries.
Malaysia ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis
Malaysia's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is projected to grow from $48 Mn in 2022 to $86 Mn in 2030 with a CAGR of 7.7% for the year 2022-30. The rise in the prevalence of ADHD cases in Malaysia and the demand for novel treatment options are responsible for the growth of the market. The Malaysia ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Royce Pharma, GoodScience, and Eli Lilly are some of the key players in the market.
Malaysia Robotic Surgery Services Market Analysis
This report presents a strategic analysis of the Malaysia Robotic Surgery Services Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Malaysia Robotic Surgery Services Market, offering unmatched value, accuracy and expert insights.
Malaysia Dental Care Market Analysis
The Malaysia Dental Care Services Market size is at around $57.69 Mn in 2022 and is projected to reach $94.76 in 2030, exhibiting a CAGR of 6.4% during the forecast period (2022-2030). Malaysia spends 3.83% of its GDP on healthcare, for a total per capita distribution of $437, and provides universal healthcare to all citizens and legal residents, with tourists benefiting from competitive prices. This report by Insights10 is segmented by treatment type, age group, clinical setup, and by demography.
Malaysia Dermatological Therapeutics Market Analysis
Malaysia Dermatological Therapeutics Market is at around $0.07 Bn in 2023 and is projected to reach $0.12 Bn in 2030, exhibiting a CAGR of 8.8% during the forecast period. The market is being driven by rising healthcare awareness, an increase in dermatological conditions, and technological advancements. The market is dominated by key players like Pharmaniaga Berhad, Duopharma Biotech Berhad, Almirall SA, Pfizer Inc., GlaxoSmithKline Plc, AbbVie Inc., Amgen Inc., Novartis AG, Roche, Sanofi, Bayer, and Johnson & Johnson.
Malaysia Healthcare Insurance Market Analysis
The Malaysia healthcare insurance market is projected to grow from $3.26 Bn in 2022 to $5.94 Bn by 2030, registering a CAGR of 7.8% during the forecast period of 2022-2030. The main factors driving the growth would be increasing healthcare costs, government initiatives, a rise in medical tourism and technological advancements. The market is segmented by the component, provider, coverage, by health insurance plans and end-user. Some of the major players include Tune Protect, Etiqa Insurance, Hong Leong Assurance, Great Eastern Life Assurance and Generali.
Malaysia Cholesterol Therapeutics Market Analysis
The Malaysia Cholesterol Therapeutics Market is anticipated to experience a growth from $39 Mn in 2022 to $49 Mn by 2030, with a CAGR of 2.8 % during the forecast period of 2022-2030. The key drivers in the Malaysia Cholesterol Therapeutics Market encompass a combination of lifestyle factors, government initiatives, pharmaceutical innovations, and demographic trends which collectively contribute to the growth and evolution of the market. The Malaysia Cholesterol Therapeutics Market encompasses various players across different segments such as Pfizer, AstraZeneca, Merck, Novartis, Sanofi, Bayer, Duopharma, Apex Healthcare, Pharmaniaga, Healthex, etc, among various others.
Malaysia Patient Support Programs (PSP) Market Analysis
This report presents a strategic analysis of the Malaysia Patient Support Programs (PSP) Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Malaysia Patient Support Programs (PSP) Market, offering unmatched value, accuracy and expert insights.
Malaysia Cardiac Arrhythmia Therapeutics Market Analysis
Malaysia Cardiac Arrhythmia Therapeutics Market valued at $12 Mn in 2022, projected to reach $18 Mn by 2030 with a 6% CAGR. The key drivers of this industry include the rising prevalence of cardiac arrhythmias, supportive government initiatives, and growing treatment options. The industry is primarily dominated by players such as Abbott, Philips Healthcare, Boston Scientific, GE Healthcare, and Siemens among others.
Malaysia Cardiac Monitoring Devices Market Analysis
This report presents a strategic analysis of the Malaysia Cardiac Monitoring Devices Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Malaysia Cardiac Monitoring Devices Market, offering unmatched value, accuracy, and expert insights.
Malaysia Advanced Therapy Medicinal Products (ATMPs) Market Analysis
This report presents a strategic analysis of the Malaysia Advanced Therapy Medicinal Products (ATMPs) Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Malaysia Advanced Therapy Medicinal Products (ATMPs) Market, offering unmatched value, accuracy and expert insights.
Malaysia Alzheimer’s Therapeutics Market Analysis
Malaysia alzheimer’s therapeutics market valued at $8 Mn in 2022, projected to reach $16 Mn by 2030 with a 9.3% CAGR. The market for medications used to treat Alzheimer's disease is mostly driven by the condition's increasing prevalence, which is fuelled by an aging population. The leading pharmaceutical companies currently operating in the market are Pfizer, Novartis, Johnson & Johnson, Roche, Eli Lilly, Biogen, AstraZeneca, Merck & Co., AbbVie and Eisai.
Malaysia Atopic Dermatitis Therapeutics Market Analysis
The Malaysia Atopic Dermatitis Therapeutics Market was valued at US $20 Mn in 2022, and is predicted to grow at (CAGR) of 9% from 2023 to 2030, to US $39 Mn by 2030. The key drivers of this industry include increasing disease burden of Atopic Dermatitis (AD), supportive government policies, and technological advancements. The industry is primarily dominated by players such as Meda, Ivax, Pharmaniaga, Marufa, Sanofi, Novartis, Johnson & Johnson, and AbbVie among others.
Malaysia Atherosclerosis Therapeutics Market Analysis
Malaysia Atherosclerosis Therapeutics Market was valued at $5 Mn in 2022 and is estimated to reach $7 Mn in 2030, exhibiting a CAGR of 5.9% during the forecast period. The demand for atherosclerosis treatments is expected to rise due to the growing cases of cardiovascular diseases, escalated by unhealthy eating habits, inactive lifestyles, and a globally aging population. The top leading pharmaceutical companies presently operating in the industry are Novartis, Pfizer, AstraZeneca, Eisai, Merck Sharp & Dohme, Sanofi, Bayer, Abbott, Johnson & Johnson and Roche
Malaysia Asthma and COPD Therapeutics Market Analysis
The Malaysia Asthma and COPD Therapeutics Market was valued at US $54 Mn in 2022, and is predicted to grow at (CAGR) of 5.40% from 2023 to 2030, to US $82 Mn by 2030. The key drivers of this industry include the rising prevalence of COPD and asthma, supportive government initiatives, improved healthcare infrastructure, and others. The industry is primarily dominated by players such as AstraZeneca, Novartis, Chiesi, Sanofi, Pfizer, and GlaxoSmithKline, among others.
Malaysia HIV Drugs Market Analysis
Malaysia HIV Drugs Market is at around $50.72 Mn in 2023 and is projected to reach $65.85 Mn in 2030, exhibiting a CAGR of 3.8% during the forecast period. The market is growing as a result of government initiatives, rising HIV prevalence, and the expansion of healthcare infrastructure. The market is dominated by key players like Pharmaniaga Berhad, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffmann-La Roche Ltd., and Novartis.
Malaysia Antifungal Drugs Market Analysis
Malaysia Antifungal Drugs Market is at around $0.025 Bn in 2023 and is projected to reach $0.033 Bn in 2030, exhibiting a CAGR of 4% during the forecast period. The market is being driven by rising rates of fungal infections, rising healthcare costs, and improvements in healthcare infrastructure. The market is dominated by key players like Pharmaniaga Bhd., Duipharma Biotech Bhd., Pfizer Inc., Novartis AG, Merck & Co., Inc., Abbott Laboratories, Astellas Pharma Inc., GlaxoSmithKline plc, Bayer AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
Malaysia Axial Spondyloarthritis (axSpA) Market Analysis
Malaysia Axial Spondyloarthritis (axSpA) Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. With ongoing research and development efforts, the expansion of treatment options, and increasing patient awareness, the axSpA market is expected to witness significant growth in the coming years. AbbVie Inc., Amgen Inc., Johnson & Johnson, Novartis International AG, Pfizer Inc., Eli Lilly and Company, Merck & Co., UCB S.A., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH are the global key players in axSpA market.
Malaysia Biological Safety Testing Market Analysis
Malaysia Biological safety testing Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The biological safety testing market is driven by increasing demand for biologics, stringent regulatory requirements, rising incidence of infectious diseases, technological advancements, and growth in the biotechnology and pharmaceutical industries. Charles River Laboratories International, Merck KGaA, Lonza Group Ltd., Eurofins Scientific, SGS SA, WuXi AppTec, Toxikon Corporation, Avista Pharma Solutions, Nelson Laboratories, Pace Analytical Services are among the global key players.
Malaysia Biosimilar Monoclonal Antibodies Market Analysis
Malaysia Biosimilar Monoclonal Antibodies Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Market drivers for biosimilar monoclonal antibodies include rising demand for low-cost biologics, the increasing frequency of chronic diseases, and the need for more economical biologic therapeutics. Among the key global pharmaceutical companies in the Biosimilar Monoclonal Antibodies Market are Samsung Bioepis Co., Celltrion Inc., Biocon Ltd., Pfizer Inc., Amgen Inc., Novartis AG (Sandoz), Mylan N.V., Boehringer Ingelheim International GmbH, Fresenius Kabi AG, and Teva Pharmaceutical Industries Ltd.
Malaysia Biosimilars Market Analysis
Malaysia Biosimilars Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Cost-effectiveness, patent expirations of reference biologics, increasing demand for biologic medicines, a supportive regulatory environment, and increased acceptance by healthcare professionals are all main drivers in the biosimilars market. Novartis AG, Pfizer Inc., Amgen Inc., Coherus Biosciences Inc., Mylan NV (Viatris Inc.), and Samsung Bioepis Co., Ltd. are among the top competitors in the studied market.
Malaysia Blood Plasma Market Analysis
Malaysia Blood Plasma Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Rising demand for plasma-derived therapies, advancements in plasma fractionation technologies, rising awareness and adoption of plasma-derived therapies, a favourable regulatory environment, increased investment in plasma collection centres, and a growing need for blood plasma in research and development are key drivers in the blood plasma market. CSL Behring, Grifols, Octapharma, Biotest AG, and Kedrion are some of the major global competitors in the blood plasma industry.